These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 16869786)

  • 1. Making progress through molecular attacks on cancer.
    Sawyers CL
    Cold Spring Harb Symp Quant Biol; 2005; 70():479-82. PubMed ID: 16869786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia.
    Michor F
    Trends Pharmacol Sci; 2007 May; 28(5):197-9. PubMed ID: 17412430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to targeted therapy in chronic myelogenous leukemia.
    Hochhaus A; Erben P; Ernst T; Mueller MC
    Semin Hematol; 2007 Jan; 44(1 Suppl 1):S15-24. PubMed ID: 17292737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of interferon-alpha in the treatment of chronic myeloid leukemia.
    Kujawski LA; Talpaz M
    Cytokine Growth Factor Rev; 2007; 18(5-6):459-71. PubMed ID: 17703986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Le Tourneau C; Vidal L; Siu LL
    Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
    Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.
    O'Connor R; Clynes M; Dowling P; O'Donovan N; O'Driscoll L
    Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):805-17. PubMed ID: 18028026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy in chronic myeloid leukemia.
    Jabbour E; Cortes JE; Ghanem H; O'Brien S; Kantarjian HM
    Expert Rev Anticancer Ther; 2008 Jan; 8(1):99-110. PubMed ID: 18095887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment.
    Miething C; Grundler R; Mugler C; Brero S; Hoepfl J; Geigl J; Speicher MR; Ottmann O; Peschel C; Duyster J
    Proc Natl Acad Sci U S A; 2007 Mar; 104(11):4594-9. PubMed ID: 17360569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors.
    Ou J; Vergilio JA; Bagg A
    Am J Hematol; 2008 Apr; 83(4):296-302. PubMed ID: 17957805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New approaches to molecular cancer therapeutics.
    Collins I; Workman P
    Nat Chem Biol; 2006 Dec; 2(12):689-700. PubMed ID: 17108987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular imaging to select cancer therapy and evaluate treatment response.
    Mankoff DA
    Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):181-92. PubMed ID: 19293766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
    Tanaka R; Kimura S
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic pharmacogenomics in cancer.
    Ikediobi ON
    Pharmacogenomics J; 2008 Oct; 8(5):305-14. PubMed ID: 18679398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted cancer therapy: promise and reality.
    Klein S; Levitzki A
    Adv Cancer Res; 2007; 97():295-319. PubMed ID: 17419951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers for lung cancer: clinical uses.
    Greenberg AK; Lee MS
    Curr Opin Pulm Med; 2007 Jul; 13(4):249-55. PubMed ID: 17534168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular markers and targets for colorectal cancer prevention.
    Janakiram NB; Rao CV
    Acta Pharmacol Sin; 2008 Jan; 29(1):1-20. PubMed ID: 18158862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roots of imatinib resistance: a question of self-renewal?
    Burchert A
    Drug Resist Updat; 2007; 10(4-5):152-61. PubMed ID: 17683977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecularly targeted therapy for malignant glioma.
    Sathornsumetee S; Reardon DA; Desjardins A; Quinn JA; Vredenburgh JJ; Rich JN
    Cancer; 2007 Jul; 110(1):13-24. PubMed ID: 17520692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.